贝伐单抗一线治疗结直肠癌进展后二线应用的临床生存获益:来自于BRiTE的研究
The Journal of Evidence-Based Medicine（2009）
摘要
1 文献来源
Grothey A, Sugrue MM, Purdre DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study(BRiTE) [J]. J Clin Oncol, 2008,26 (33):5326-5334.
更多关键词
overall survival,colorectal neoplasms,Bevacizumab
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要